| Full Name | Emilee Jo Bocker |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 305 E Joe Dr, Amboy, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265726327 | NPI | - | NPPES |
| 036134064 | Medicaid | IL | |
| F400168653 | Other | IL | MEDICARE-KATHERINE SHAW BETHEA HOSPITAL |
| F400148570 | Other | IL | MEDICARE-KSB MED GROUP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 036.134064 (Illinois) | Secondary |
| 207Q00000X | Family Medicine | 036.134064 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home Health Care Of Ksb Hospit | Dixon, IL | Home health agency |
| Unity Hospice Of Western Illinois | Rochelle, IL | Hospice |
| Katherine Shaw Bethea Hospital | Dixon, IL | Hospital |
| Cgh Medical Center | Sterling, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ksb Medical Group Inc | 7911890009 | 78 |
News Archive
In this PBS NewsHour report, NewsHour correspondent Spencer Michels interviews obstetrician Laura Stachel about the "solar suitcase," a "a suitcase containing elements to produce and store solar energy," devised by Stachel with the aim of reducing maternal mortality rates in the developing world after "witnessing the consequences of power outages in Nigeria's health facilities."
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
How cool is this: the Massachusetts General Hospital laboratory that invented cryolipolisis or "Coolsculpting," a popular non-surgical method for reducing fat under the skin, is developing a new form of the technology that can selectively reduce fat almost anywhere in the body using a safe, injectable ice solution or "slurry."
"WellPoint Inc. has warned some 470,000 people who applied for its health insurance that a website security glitch may have exposed their Social Security numbers and other sensitive data to the public." WellPoint quickly fixed the problem after being notified by a consumer who noticed it. The glitch "was introduced in October by a contractor who upgraded the site," according to a company spokesman. According to WellPoint officials, the "security glitch was exploited to access information on 940 insurance applications" and "unauthorized viewers accessed spreadsheets that 'in rare cases' contained Social Security numbers" (Finkle, 6/29).
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
› Verified 3 days ago
| Entity Name | Ksb Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073592119 PECOS PAC ID: 7911890009 Enrollment ID: O20040203000860 |
News Archive
In this PBS NewsHour report, NewsHour correspondent Spencer Michels interviews obstetrician Laura Stachel about the "solar suitcase," a "a suitcase containing elements to produce and store solar energy," devised by Stachel with the aim of reducing maternal mortality rates in the developing world after "witnessing the consequences of power outages in Nigeria's health facilities."
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
How cool is this: the Massachusetts General Hospital laboratory that invented cryolipolisis or "Coolsculpting," a popular non-surgical method for reducing fat under the skin, is developing a new form of the technology that can selectively reduce fat almost anywhere in the body using a safe, injectable ice solution or "slurry."
"WellPoint Inc. has warned some 470,000 people who applied for its health insurance that a website security glitch may have exposed their Social Security numbers and other sensitive data to the public." WellPoint quickly fixed the problem after being notified by a consumer who noticed it. The glitch "was introduced in October by a contractor who upgraded the site," according to a company spokesman. According to WellPoint officials, the "security glitch was exploited to access information on 940 insurance applications" and "unauthorized viewers accessed spreadsheets that 'in rare cases' contained Social Security numbers" (Finkle, 6/29).
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
› Verified 3 days ago
| Entity Name | Katherine Shaw Bethea Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427043546 PECOS PAC ID: 2264480037 Enrollment ID: O20081218000029 |
News Archive
In this PBS NewsHour report, NewsHour correspondent Spencer Michels interviews obstetrician Laura Stachel about the "solar suitcase," a "a suitcase containing elements to produce and store solar energy," devised by Stachel with the aim of reducing maternal mortality rates in the developing world after "witnessing the consequences of power outages in Nigeria's health facilities."
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
How cool is this: the Massachusetts General Hospital laboratory that invented cryolipolisis or "Coolsculpting," a popular non-surgical method for reducing fat under the skin, is developing a new form of the technology that can selectively reduce fat almost anywhere in the body using a safe, injectable ice solution or "slurry."
"WellPoint Inc. has warned some 470,000 people who applied for its health insurance that a website security glitch may have exposed their Social Security numbers and other sensitive data to the public." WellPoint quickly fixed the problem after being notified by a consumer who noticed it. The glitch "was introduced in October by a contractor who upgraded the site," according to a company spokesman. According to WellPoint officials, the "security glitch was exploited to access information on 940 insurance applications" and "unauthorized viewers accessed spreadsheets that 'in rare cases' contained Social Security numbers" (Finkle, 6/29).
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emilee Jo Bocker, MD 305 E Joe Dr, Amboy, IL 61310 Ph: (815) 857-3044 | Emilee Jo Bocker, MD 305 E Joe Dr, Amboy, IL 61310 Ph: (815) 857-3044 |
News Archive
In this PBS NewsHour report, NewsHour correspondent Spencer Michels interviews obstetrician Laura Stachel about the "solar suitcase," a "a suitcase containing elements to produce and store solar energy," devised by Stachel with the aim of reducing maternal mortality rates in the developing world after "witnessing the consequences of power outages in Nigeria's health facilities."
The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.
How cool is this: the Massachusetts General Hospital laboratory that invented cryolipolisis or "Coolsculpting," a popular non-surgical method for reducing fat under the skin, is developing a new form of the technology that can selectively reduce fat almost anywhere in the body using a safe, injectable ice solution or "slurry."
"WellPoint Inc. has warned some 470,000 people who applied for its health insurance that a website security glitch may have exposed their Social Security numbers and other sensitive data to the public." WellPoint quickly fixed the problem after being notified by a consumer who noticed it. The glitch "was introduced in October by a contractor who upgraded the site," according to a company spokesman. According to WellPoint officials, the "security glitch was exploited to access information on 940 insurance applications" and "unauthorized viewers accessed spreadsheets that 'in rare cases' contained Social Security numbers" (Finkle, 6/29).
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
› Verified 3 days ago